Innovation Acta News
2019
-
NOV29
RESTORE 1ATSM international press release
1st Advanced Therapies Science Meeting
25-26 Nov 2019, Berlin, Germany
-
SEP26
RESTORE 1ATSM programme
1ATSM has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®).
1ATSM is further accredited by the by the Ärztekammer Berlin.
-
JUL18
RESTORE 1ATSM Registration Open
1st Advanced Therapies Science Meeting Registration Open
25-26 Nov 2019, Berlin, Germany
The conference will highlight the science behind Advanced Therapies with a jam-packed agenda featuring leaders in science and technology development.
Join us to:
Explore the latest highlights and discuss the most pressing challenges from the field of Advanced Therapies.
Engage with leaders in research, technology development and clinical application.
Contribute with talks and posters to the first Advanced Therapies Science Meeting: Abstract submisison
-
MAY6-7
RESTORE Kick-off Meeting
6-7 May 2019, Berlin, Germany
RESTORE Partners and Supporters will meet to jointly flesh out the details of the Advanced Therapies Roadmap 2021-30
We have reached the total number of participants and the registration to the event is therefore no more available. If you are interested in participating to the next activities, do not hesitate to follow RESTORE on Facebook and Twitter
-
MAR1
RESTORE officially starts
Today marks the official start of RESTORE - Health by Advanced Therapies, entering the preparatory phase to become a Large-Scale Research Initiative.
-
FEB7
RESHAPE Kick-off Meeting
RESHAPE Kick-off Meeting
The project kick-off meeting takes places on 07-08 February in Berlin (Germany) -
FEB8
RESTORE – Large Scale Research Initiative – will receive initial funding
Shifting from treating symptoms to curing diseases and making Europe the world leader in Advanced Therapies is the aspiration of RESTORE – the Large-Scale Research Initiative, led by Charité. On February 8, the European Commission (EC) backed that vision and announced that RESTORE will receive initial funding of EUR 1m and invited the consortium to fully develop their concept and to further expand the community that strives to propel Europe to the forefront in Advanced Therapies.
-
JAN16-17
NECESSITY kick-off Meeting
The kick-off meeting for the IMI2 JU-funded “NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients” NECESSITY Project took place in Paris on January 16th-17th, 2019. The NECESSITY project consortium is presently made up of twenty-five partners, twenty of which are academic institutions, four are EFPIA member companies and one (INN-ACTA) is a small and medium enterprise (SME). Nine countries are represented: France, The United Kingdom, Italy, Spain, Switzerland, Norway, United States, the Netherlands, Sweden and Greece.
-
JAN1
NECESSITY officially starts
The main objectives of the NECESSITY Project are:
1) To develop and assess sensitive clinical endpoints to evaluate response to drug treatments in patients affected by the Primary Sjögren’s syndrome (pSS);
2) To identify and evaluate discriminative biomarkers for stratification of pSS patients;
3) To design and perform a multi-arm multi-stage clinical trial to validate the newly defined pSS endpoints and the identified biomarkers.The kick-off meeting of the project took place in Paris on 16-17 January 2019
Interested in contributing to the development of the European or National Projects? Join us by filling our collaboration form to be involved in any new opportunity tailored to your interests:
